Literature DB >> 16891098

Treatment of experimental chronic pulmonary mycoplasmosis.

Monica Fonseca-Aten1, Ana Maria Rios, Asuncion Mejias, Susana Chavez-Bueno, Kathy Katz, Ana Maria Gomez, Octavio Ramilo, George H McCracken, R Doug Hardy.   

Abstract

Mycoplasma pneumoniae infection has been associated with chronic lung disease. Treatment of chronic pulmonary mycoplasmosis has not been well investigated. BALB/c mice were intranasally inoculated once with M. pneumoniae or with sterile media (uninfected controls). Infected mice were treated with telithromycin or placebo daily for 10 days in the chronic phase of disease (18 months after inoculation). Mice (n=43) were evaluated before therapy and 1 day after completion of telithromycin. Treatment of infected mice with telithromycin at 18 months after infection significantly reduced chronic pulmonary histological inflammation compared with infected mice given placebo; however, this treatment did not improve airway obstruction or airway hyperresponsiveness. Therapy longer than 10 days may be necessary to improve pulmonary function.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16891098     DOI: 10.1016/j.ijantimicag.2006.04.008

Source DB:  PubMed          Journal:  Int J Antimicrob Agents        ISSN: 0924-8579            Impact factor:   5.283


  2 in total

1.  Efficacy of increasing dosages of clarithromycin for treatment of experimental Mycoplasma pneumoniae pneumonia.

Authors:  C Tagliabue; C Techasaensiri; J P Torres; K Katz; C Meek; T R Kannan; J J Coalson; S Esposito; N Principi; R Leff; J B Baseman; R D Hardy
Journal:  J Antimicrob Chemother       Date:  2011-07-25       Impact factor: 5.790

2.  The impact of steroids given with macrolide therapy on experimental Mycoplasma pneumoniae respiratory infection.

Authors:  C Tagliabue; C M Salvatore; C Techasaensiri; A Mejias; J P Torres; K Katz; A M Gomez; S Esposito; N Principi; R D Hardy
Journal:  J Infect Dis       Date:  2008-10-15       Impact factor: 5.226

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.